RESEARCH AREA

Alzheimer’s Disease (AD)

Alzheimer’s Disease is a progressive and eventually fatal brain disease, responsible for 60-80% of all dementia cases. The disease processes begin decades before the onset of symptoms, making early detection and intervention a priority.

We are not currently recruiting for clinical trials related to Alzheimer’s Disease. If you are interested in participating in future studies, please complete our

Research Participation Form.

Completed Trials:

2018: 1346.23 study (Phase II)
2017: CREAD 2 study (Phase III)
2009: EMBRACE study (Phase IV)

RESEARCH AREA

Cognitive Impairment Clinic

At Clinique Neuro-Outaouais, our mission is to provide the best neurological outcomes possible. It is in keeping with this goal that we pursue several different avenues of clinical research; it’s also why we continue to expand the range of our therapies. Offering a wider breadth of neurological care not only provides the Greater Gatineau region with the most recent treatment options, it also makes it possible to tailor treatments, which often leads to better outcomes.

Available Studies

The Cognitive Impairment Clinic (CIC)

The (CIC) is our latest initiative. It was spearheaded to address the acute and growing need of Gatineau’s aging population, and the concomitantly growing difficulty of this population to access MDs able to follow those affected by cognitive disorders.

The CIC Team

The Cognitive Impairment Clinic is composed of nurses, neurologists and PhD neuroscientists. It has developed an expertise in the assessment and continuous care of Cognitive Impairments. This includes, but is not limited to Alzheimer’s, Dementia, and Parkinson’s.

Alzheimer’s as a specialty

Alzheimer’s currently has no cure and affects 1 out of every 5 people over 80. Due to its growing impact, Clinique Neuro-Outaouais’ team is committed to being proactive in the search for treatments to alleviate this disease.

Cognitive impairment can manifest in different ways, consult your MD if you experience the following:

  • Memory loss
  • Language or word finding difficulties
  • Difficulty naming or recognizing objects or people
  • Significant fluctuation of cognitive function
  • Behavioral changes: disinhibition / apathy-indifference / inappropriate social behavior
  • Difficulty completing previously learned tasks or activities
  • New onset of paranoia or self-isolation.

How to access the CIC?

To access the services of the CIC, you should ask your referring physician to refer you specifically to Clinique Neuro-Outaouais or the CIC.

Maladie d’Alzheimer (MA)

La maladie d’Alzheimer est une affection cérébrale évolutive et, à terme, fatale. Elle est responsable de 60 à 80 % des cas de démence. Les atteintes cérébrales débutent souvent des décennies avant les premiers symptômes, d’où l’importance du dépistage et des interventions précoces.

Participer

Essais cliniques en recrutement

Aucune étude en cours actuellement .

Si vous souhaitez participer à de futures études, veuillez remplir notre formulaire de participation à la recherche.

Essais cliniques en cours

Aucun essai clinique en cours pour le moment.

Essais cliniques terminés

2018: Étude 1346.23 (Phase II)
2017: Étude CREAD 2 (Phase III)
2009: Étude EMBRACE (Phase IV)

Participate as a Healthy Volunteer

Please fill the form below and we will get back to you.